Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on February 13, 2023, covering events occurring on February 7, 2023. The filing addresses the confirmation of a significant arbitration award against Sorrento Therapeutics, Inc. by the Los Angeles County Superior Court.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the confirmed judgment amount:
- Total Judgment: Approximately $176.37 million plus 10% post-judgment interest.
- Amount Payable to NantCell, Inc. (Wholly-owned subsidiary): Approximately $159.42 million.
- Amount Payable to Immunotherapy NANTibody, LLC (Joint Venture): The remainder of the total judgment.
Material Changes and Legal Developments
The material event is the court's confirmation of a final arbitration award originally executed on December 2, 2022. Key developments include:
- Confirmation of Award: The court confirmed the award finding Sorrento breached exclusive license agreements, originally totaling $173.5 million plus prejudgment interest.
- Declaratory Relief: The court determined that license agreements remain in full force regarding ImmunityBio's PD-L1 NK cell, while Sorrento has no further rights or obligations regarding other targets.
- Injunction Granted: The court issued an injunction preventing Sorrento from making overseas transfers over $1 million or certain transfers to insiders until the award is paid.
- Denial of Vacatur: Sorrento's motion to vacate the award was denied.
Outlook, Risks, and Management Commentary
Management intends to vigorously pursue the collection of the judgments and accrued interest. However, the filing explicitly states that no assurances are made regarding the receipt of the full amount or the timing of such receipt. Other previously disclosed disputes between the Company's affiliates and Sorrento remain pending, and the Company intends to defend against any claims asserted against it.
Investor Verification Checklist
- Verify the current liquidity status of Sorrento Therapeutics, Inc. to assess the collectability of the $176.37 million judgment.
- Monitor the status of the injunction preventing asset transfers by Sorrento.
- Review the status of other pending Superior Court actions between ImmunityBio affiliates and Sorrento.
- Confirm the specific breakdown of the joint venture's share of the judgment versus the subsidiary's share.